Nuclera raises additional capital for eProtein™ desktop bioprinter to close Series B funding at $58M.
Summary
However, Nucleras eProtein bioprinter combines cell-free protein synthesis and digital microfluidics to create a novel technology platform that solves this problem within 24 hours revolutionizing the fragmented protein expression screening system into a single optimized, end-to-end workflow for drug discovery and general bio-innovation.The eProtein bioprinter will allow researchers to accelerate discoveries and treatments by delivering on-demand, desktop access. The days of screening a single protein expression profile at a time are coming to an end with this technology.Nuclera is excited to continue their preparation for successful commercial launch and will use the funds to support this work. The company is currently in the process of conducting alpha testing with select, key customers to gather market intelligence and shape the full commercial launch.Co-founder and Nuclera CEO Michael Chen said, Were delighted by the continued support from our existing investors and to have the opportunity to bring on several new strategic partners with our recent Series B raise. Im thrilled to advance our mission of making proteins accessible and continue on our journey to deliver our game-changing technology to the market.Nuclera was advised by leading international law firm, Taylor Wessing LLP. Led by partner Ross McNaughton, this is the latest investment opportunity the firm has supported Nuclera on in strategic growth plans to revolutionize access to biology.